Investors Face March 24 Deadline in Beyond Meat Securities Class Action

Beyond Meat's stock was trading below $1.40 when the company disclosed in November 2025 that it would delay its third-quarter earnings report to complete an impairment review. By the time the plant-based meat company's CFO confirmed the damage on a November 11 investor call, the share price had shed more than a third of its value across three separate drops. The March 24, 2026 deadline for investors to seek appointment as lead plaintiff in a federal securities class action against Beyond Meat, Inc. (NASDAQ: BYND) passed yesterday, closing a window that multiple securities litigation firms had spent weeks publicizing.

The complaint alleges that Beyond Meat and its executives violated federal securities laws by making false and misleading statements and failing to disclose that the book value of certain long-lived assets exceeded their fair value, making it highly likely the company would be required to record a material, non-cash impairment charge, and that this was likely to impair Beyond Meat's ability to timely file its periodic reports with the SEC.

The sequence of events that formed the factual backbone of the lawsuit unfolded rapidly in the fall of 2025. On November 3, 2025, during pre-market hours, Beyond Meat announced it would delay reporting its Q3 2025 financial results, citing the need for additional time to complete its impairment review; the stock fell $0.265 per share, or 16.01%, to close at $1.39 that day. When Beyond Meat finally released Q3 results on November 10, 2025, it reported a loss from operations of $112.3 million, which included "$77.4 million in non-cash impairment charges related to certain of the Company's long-lived assets." On that news, the stock fell another $0.12 per share, or 8.96%, to close at $1.22 on November 11, 2025. The following trading day, the shares fell an additional $0.105 per share, or 8.61%, to close at $1.115 on November 12, 2025.

The class action covers investors who purchased or otherwise acquired Beyond Meat securities during the period from February 27, 2025 through November 11, 2025. Faruqi & Faruqi, LLP, the New York-based securities litigation firm that ran the most sustained public campaign around the deadline, issued notices urging eligible shareholders to contact securities litigation partner James (Josh) Wilson directly. The firm has offices in New York, Pennsylvania, California and Georgia and has recovered hundreds of millions of dollars for investors since its founding in 1995.

The Beyond Meat deadline was one of several running simultaneously. Faruqi also reminded investors of the March 24, 2026 deadline in connection with a separate federal securities class action against BlackRock TCP Capital Corp. (NASDAQ: TCPC), covering purchasers who acquired securities between November 6, 2024 and January 23, 2026. On the same day, Faruqi circulated a notice for Concorde International Group, Ltd. (NASDAQ: CIGL), with a later deadline of May 20, 2026, while also alerting Pomdoctor Limited (NASDAQ: POM) investors of an April 13, 2026 cutoff covering purchases between October 9, 2025 and December 11, 2025.

The Rosen Law Firm separately reminded investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) of an April 7, 2026 lead plaintiff deadline, with a class period stretching from October 10, 2023 through December 26, 2025. In its notice, Rosen offered pointed advice about counsel selection, cautioning that "many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases."

Under federal securities law, the court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class; any class member may move the court to serve as lead plaintiff or choose to remain an absent class member, and the decision does not affect the right to share in any recovery. Investors who missed yesterday's BYND deadline can still remain class members, though the window to seek the lead plaintiff role has closed.